Control of IgE responses. 4. Isotype-specific suppression of peak BPO-specific IgE antibody-forming cell responses and of BPO-specific IgE in serum by muramyldipeptide or murabutide after administration to mice by gavage.
Muramyldipeptide (MDP) and murabutide (MB) suppressed hapten-specific IgE antibody-forming cell (AFC) responses in vivo. IgE responses were induced in BALB/c mice by intraperitoneal injection with benzylpenicilloyl-keyhole limpet hemocyanin (BPO-KLH) (10 micrograms) in aluminum hydroxide gel (Alum) on days 0, 21 and 42. On day 44, mice were fed (gavage) or injected subcutaneously with varying concentrations of MDP or MB (0.1-500 mg/kg). The mice were killed on days 45-70, and the numbers of BPO-specific IgM, IgG1, IgE, and IgA AFC in various lymphoid organs were determined in an enzyme-linked immunosorbent spot (ELISPOT) assay. In addition, levels of BPO-specific IgE in serum were determined by ELISA. Data are expressed as AFC/10(7) cells or as micrograms/ml. Feeding with MDP or MB on day 44 suppressed BPO-specific IgE AFC responses and serum levels of BPO-specific IgE within 48 h (day 46) (65-100% and approximately 50% decrease, respectively). With both molecules, the suppression was IgE isotype-specific, dose-dependent and transient. The suppression was also route-specific since it was obtained only when MDP or MB were given by gavage, and not when injected subcutaneously. These results show that peak antigen-specific IgE responses can be downregulated in vivo, in isotype-specific fashion, by a clearly defined class of molecules, MDP and MB, one of which, MB, is a candidate for clinical studies in man. The mechanism of suppression probably involves the modulation of gut-associated lymphoid tissue and mucosal immunity. The clinical implications are that pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic downregulation of IgE and, hence, in the therapy of IgE-mediated diseases in man such as allergic rhinitis, asthma, and other atopic diseases.
Department of Pathology, State University of New York Health Science Center, Brooklyn 11203-2098.
D L
DL
Auci
J A
JA
Carucci
S M
SM
Chice
M C
MC
Smith
P
P
Dukor
H G
HG
Durkin
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000818:Animals; D000921:Antibody-Producing Cells / Q000276:immunology*; D044482:Benzeneacetamides; D004797:Enzyme-Linked Immunosorbent Assay; D006433:Hemocyanins / Q000276:immunology; D007073:Immunoglobulin E / Q000276:immunology*; D007132:Immunoglobulin Isotypes / Q000276:immunology*; D007136:Immunoglobulins / Q000276:immunology; D007165:Immunosuppression Therapy; D007279:Injections, Subcutaneous; D008221:Lymphoid Tissue / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010400:Penicillin G / Q000031:analogs & derivatives* / Q000276:immunology
D000276:Adjuvants, Immunologic; D044482:Benzeneacetamides; D007132:Immunoglobulin Isotypes; D007136:Immunoglobulins; C015026:benzylpenicilloyl G; D007073:Immunoglobulin E; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C033575:murabutide; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin; D010400:Penicillin G